Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Proteomics International Laboratories Ltd. (AU:PIQ)
ASX:PIQ
Proteomics International Laboratories Ltd. (PIQ) Share Price & Analysis
3 Followers
PIQ Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.70 - AU$1.40
Previous CloseAU$1.14
Volume19.99K
Average Volume (3M)323.30K
Market Cap
AU$149.22M
Enterprise ValueAU$147.11M
Total Cash (Recent Filing)AU$2.11M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)-23.3
Beta0.92
Next Earnings
Aug 28, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding130,892,616
10 Day Avg. Volume188,914
30 Day Avg. Volume323,298
Standard Deviation0.20
R-Squared0.00142
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Proteomics International Laboratories Ltd. News
Options Prices
Currently, No data available
---
Ownership Overview
20.26% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
79.74% Public Companies and
Individual Investors
PIQ FAQ
What was Proteomics International Laboratories Ltd.’s price range in the past 12 months?
Proteomics International Laboratories Ltd. lowest share price was AU$0.70 and its highest was AU$1.40 in the past 12 months.
What is Proteomics International Laboratories Ltd.’s market cap?
Currently, no data Available
When is Proteomics International Laboratories Ltd.’s upcoming earnings report date?
Proteomics International Laboratories Ltd.’s upcoming earnings report date is Aug 28, 2024 which is in 121 days.
How were Proteomics International Laboratories Ltd.’s earnings last quarter?
Proteomics International Laboratories Ltd. released its earnings results on Feb 23, 2024. The company reported -AU$0.03 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.03.
Is Proteomics International Laboratories Ltd. overvalued?
According to Wall Street analysts Proteomics International Laboratories Ltd.’s price is currently Overvalued.
Does Proteomics International Laboratories Ltd. pay dividends?
Proteomics International Laboratories Ltd. does not currently pay dividends.
What is Proteomics International Laboratories Ltd.’s EPS estimate?
Proteomics International Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Proteomics International Laboratories Ltd. have?
Proteomics International Laboratories Ltd. has 130,892,610 shares outstanding.
What happened to Proteomics International Laboratories Ltd.’s price movement after its last earnings report?
Proteomics International Laboratories Ltd. reported an EPS of -AU$0.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Proteomics International Laboratories Ltd.?
Currently, no hedge funds are holding shares in AU:PIQ
---
Proteomics International Laboratories Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:PIQ Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth AU$2.0M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.00%
12-Months-Change
Fundamentals
Return on Equity
-94.37%
Trailing 12-Months
Asset Growth
-22.43%
Trailing 12-Months
Company Description
Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd is a biological research and drug discovery company. The company specializes in the area of proteomics which is the industrial scale study of the structure and function of proteins. Its operations are divided into PromarkerD that targets the global diabetes epidemic and is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes; its proprietary biomarker discovery platform called Promarker, which searches for protein fingerprints in a sample; and Analytical Services that are specialist contract research focusing on biosimilars quality control and pharmacokinetic testing for clinical trials.
---
Technical Analysis
---